Emfietzoglou Maria, Terentes-Printzios Dimitrios, Kotronias Rafail A, Marin Federico, Montalto Claudio, De Maria Giovanni Luigi, Banning Adrian P
Oxford Heart Centre, Oxford University Hospitals, Oxford, UK.
Nat Cardiovasc Res. 2022 Apr;1(4):298-311. doi: 10.1038/s44161-022-00045-5. Epub 2022 Apr 13.
Microvascular dysfunction (MVD) contributes to several conditions that increase morbidity and mortality, including ischemic heart disease, heart failure, dementia, chronic kidney disease and hypertension. Consequently, MVD imposes a substantial burden on healthcare systems worldwide. In comparison to macrovascular dysfunction, MVD has been incompletely investigated, and it remains uncertain whether MVD in an organ constitutes a distinct pathology or a manifestation of a systemic disorder. Here, we summarize and appraise the techniques that are used to diagnose MVD. We review the disorders of the heart, brain and kidneys in which the role of MVD has been highlighted and summarize evidence hinting at a systemic or multi-organ nature of MVD. Finally, we discuss the benefits and limitations of implementing MVD testing in clinical practice with a focus on new interventions that are beginning to emerge.
微血管功能障碍(MVD)会导致多种增加发病率和死亡率的病症,包括缺血性心脏病、心力衰竭、痴呆、慢性肾病和高血压。因此,MVD给全球医疗系统带来了沉重负担。与大血管功能障碍相比,对MVD的研究尚不充分,器官中的MVD究竟是一种独特的病理状态还是全身性疾病的一种表现仍不明确。在此,我们总结并评估用于诊断MVD的技术。我们回顾了心脏、大脑和肾脏中MVD作用已得到突出强调的病症,并总结了表明MVD具有全身性或多器官性质的证据。最后,我们讨论在临床实践中进行MVD检测的益处和局限性,重点关注已开始出现的新干预措施。